Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Chief Development Officer | February 24, 2023 | February 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date February 24, 2023 · Filed February 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2033-02-24 | Direct | 249,080 |
Reported balance
After 2023-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-24 · Grant · Acquired 249,080 · Balance 249,080 F1: The option vests as to 25% of the option shares on February 24, 2024 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the option shares on February 24, 2024 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2023 Filed Feb 28, 2023 17:23 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (Right to buy) · Derivative | 249,080 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001437749-23-004948 · rdgdoc.xml · derivative · entry 1 Olwill Shane · CIK 0001875416 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,080 Underlying: Common Stock · 249,080 shares Expires 2033-02-24 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on February 24, 2024 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 16:47 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (Right to buy) · Derivative | 215,819 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001562180-22-001873 · primarydocument.xml · derivative · entry 1 Olwill Shane · CIK 0001875416 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,819 Underlying: Common Stock · 215,819 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on February 22, 2023 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 16:38 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | Exercise / conversionStock Option (right to buy) · Derivative | 38,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001562180-21-005712 · primarydocument.xml · derivative · entry 4 Olwill Shane · CIK 0001875416 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,600 Underlying: Common Stock · 100,000 shares Expires 2026-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option has fully vested. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 16:38 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | SaleCommon Stock | 29,200 | $5.15 | $150,380.00 |
DisclosureSEC source: 0001562180-21-005712 · primarydocument.xml · nonDerivative · entry 3 Olwill Shane · CIK 0001875416 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,638 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 to $5.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 16:38 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | SaleCommon Stock | 9,200 | $5.00 | $46,000.00 |
DisclosureSEC source: 0001562180-21-005712 · primarydocument.xml · nonDerivative · entry 2 Olwill Shane · CIK 0001875416 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,838 Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 16:38 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | Exercise / conversionCommon Stock | 38,400 | $1.52 | $58,368.00 |
DisclosureSEC source: 0001562180-21-005712 · primarydocument.xml · nonDerivative · entry 1 Olwill Shane · CIK 0001875416 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.